CALA News and Press, Calithera Biosciences Inc. From 04/13/21

Calithera Biosciences Inc. (NASDAQ:CALA) traded at a new 52-week low today of $2.08. So far today approximately 1.8 million shares have been exchanged, as compared to an average 30-day volume of 965,000 shares. In the past 52 weeks, Calithera Biosciences Inc. share prices are bracketed b...

Image source: The Motley Fool. Calithera Biosciences Inc (NASDAQ: CALA) Q4 2020 Earnings Call Mar 16, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Calithera Biosciences Inc (CALA) Q4 2020 Earnings Call Transcript...

Calithera Biosciences, Inc. (CALA) Q4 2020 Earnings Conference Call March 16, 2021 05:00 PM ET Company Participants Jennifer McNealey - VP, Investor Relations Susan Molineaux - Founder, President and CEO Keith Orford - Chief Medical Officer Stephanie Wong - Chief Financial Officer Conference ...

Calithera Biosciences (CALA): Q4 GAAP EPS of -$0.32 in-line.As of December 31, 2020, cash, cash equivalents and investments totaled $115.2 million.Shares +2.45%.Press Release For further details see: Calithera Biosciences EPS in-line

--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on March 16, 2021-- SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and dev...

SOUTH SAN FRANCISCO, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today ann...

SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today ann...

SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announce...

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...

Gainers: ObsEva (OBSV) +56%, DBV Technologies (DBVT) +44%, Senseonics Holdings (SENS) +39%, Avinger (AVGR) +33%, Bionano Genomics (BNGO) +28%.Losers: Cardiff Oncology (CRDF) -20%, SOS (SOS) -18%, Lexicon Pharmaceuticals (LXRX) -11%,&...